MediPrint Ophthalmics
PrivateLast Round
Series A
Mar 15, 2022
Total Funding Raised
$6.5M
Company Overview
MediPrint Ophthalmics is a clinical-stage pharmaceutical company developing a proprietary ocular drug delivery portfolio using drug-eluting contact lenses to treat conditions like glaucoma, dry eye, and allergies.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, 3D Printing, Clinical Trials
Business Model
B2B2C
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MediPrint Ophthalmics Comparables
Compare MediPrint Ophthalmics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Freya Ophthalmics | 89% | |
| OcuMedic, Inc. | 84% | |
| Mati Therapeutics | 81% | |
MediPrint Ophthalmics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 15, 2022 | ||||
| Seed | Jan 26, 2021 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 9, 2026
Monthly visitors increased 1050% MoM, from 34 to 391.
- Oct 29, 2024
Monthly visitors grew 337% MoM.
MediPrint Ophthalmics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about MediPrint Ophthalmics's valuation, stock price, and market status.